Nomegestrol acetate ameliorated adipose atrophy in a rat model of cisplatin‑induced cachexia

Zhong,Ruihua; Yang,Wenjie; Li,Guoting; Xie,Shuwu; Guo,Xiangjie; Zhou,Jieyun; Ren,Bingtao; Zhu,Yan

doi:10.3892/etm.2022.11723

Nomegestrol acetate ameliorated adipose atrophy in a rat model of cisplatin‑induced cachexia

Authors:
- Ruihua Zhong
- Wenjie Yang
- Guoting Li
- Shuwu Xie
- Xiangjie Guo
- Jieyun Zhou
- Bingtao Ren
- Yan Zhu
View Affiliations

Affiliations: Lab of Reproductive Pharmacology, NHC Key Lab of Reproduction Regulation, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Fudan University, Shanghai 200032, P.R. China
Published online on: November 23, 2022 https://doi.org/10.3892/etm.2022.11723
Article Number: 24
Copyright: © Zhong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cachexia, a complex disorder that results in depletion of adipose tissue and skeletal muscle, is driven by anorexia, metabolic abnormalities and inflammation. There are limited therapeutic options for this syndrome. Previous evidence has demonstrated that increasing adipose tissue may improve quality of life and survival outcomes in cachexia. Cisplatin, as a chemotherapy drug, also causes cachexia during antitumor therapy due to its adverse effects. To establish a rat model of cachexia, the animals were intraperitoneally treated with cisplatin at doses of 1, 2 and 3 mg/kg, and the rats that responded to cisplatin at the optimal dose were used to test the effect of nomegestrol acetate (NOMAc). Rats that were assessed to be sensitive to cisplatin were randomly grouped and intragastrically administered vehicle, 5 or 10 mg/kg megestrol acetate (MA) or 2.5, 5 or 10 mg/kg NOMAc. The body weights and food consumption of the rats were assessed. Serum IL‑6 and TNF‑α levels were assessed using ELISA. The protein expression levels of adipose triglyceride lipase (ATGL), hormone‑sensitive lipase (HSL), peroxisome proliferator activated receptor γ (PPARγ), fatty acid synthase (FASN) and sterol regulatory element‑binding protein‑1 (SREBP‑1) from inguinal white adipose tissue (iWAT) and epididymal white adipose tissue (eWAT) were evaluated using western blotting. The optimal way to establish a chemotherapy‑induced rat model of cachexia demonstrated in the present study was to intraperitoneally administer the rats with 2 mg/kg cisplatin for 3 consecutive days. NOMAc (2.5, 5 mg/kg) and MA (10 mg/kg) were able to significantly ameliorate the loss of body weight in the cisplatin‑induced cachectic rats. NOMAc significantly reduced the serum levels of TNF‑α at 10 mg/kg. Morphologically, iWAT atrophy, with a remarkable reduction in adipocyte volume, was observed in the cisplatin‑induced cachectic rats, but the effects were reversed by administering 5, 10 mg/kg NOMAc or 10 mg/kg MA. Furthermore, 2.5 mg/kg NOMAc markedly reduced the protein expression levels of the lipolysis genes HSL and ATGL, and 5 mg/kg NOMAc markedly enhanced the protein expression levels of adipogenesis genes, including FASN, SREBP‑1 and PPARγ in iWAT but not in eWAT. NOMAc was demonstrated to improve cachexia at lower doses compared with MA. Overall, NOMAc is likely to be a promising candidate drug for ameliorating cancer cachexia induced by cisplatin.

View Figures

View References

1	Fearon KCH: Cancer cachexia: Developing multimodal therapy for a multidimensional problem. Eur J Cancer. 44:1124–1132. 2008.PubMed/NCBI View Article : Google Scholar
2	Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, Fallon M, Herrstedt J, Lau H, Platek M, et al: Management of cancer cachexia: ASCO guideline. J Clin Oncol. 38:2438–2453. 2020.PubMed/NCBI View Article : Google Scholar
3	Baracos VE, Martin L, Korc M, Guttridge DC and Fearon KCH: Cancer-associated cachexia. Nat Rev Dis Primers. 4(17105)2018.PubMed/NCBI View Article : Google Scholar
4	Coletti D: Chemotherapy-induced muscle wasting: An update. Eur J Transl Myol. 28(7587)2018.PubMed/NCBI View Article : Google Scholar
5	Siddiqui JA, Pothuraju R, Jain M, Batra SK and Nasser MW: Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions. Biochim Biophys Acta Rev Cancer. 1873(188359)2020.PubMed/NCBI View Article : Google Scholar
6	Argilés JM, Busquets S, Stemmler B and López-Soriano FJ: Cancer cachexia: Understanding the molecular basis. Nat Rev Cancer. 14:754–762. 2014.PubMed/NCBI View Article : Google Scholar
7	Fearon K, Arends J and Baracos V: Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 10:90–99. 2013.PubMed/NCBI View Article : Google Scholar
8	Zhu X, Callahan MF, Gruber KA, Szumowski M and Marks DL: Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease-associated cachexia. J Clin Invest. 130:4921–4934. 2020.PubMed/NCBI View Article : Google Scholar
9	Lee MW, Lee M and Oh KJ: Adipose tissue-derived signatures for obesity and type 2 diabetes: Adipokines, batokines and MicroRNAs. J Clin Med. 8(854)2019.PubMed/NCBI View Article : Google Scholar
10	Chouchani ET and Kajimura S: Metabolic adaptation and maladaptation in adipose tissue. Nat Metab. 1:189–200. 2019.PubMed/NCBI View Article : Google Scholar
11	Murphy RA, Wilke MS, Perrine M, Pawlowicz M, Mourtzakis M, Lieffers JR, Maneshgar M, Bruera E, Clandinin MT, Baracos VE and Mazurak VC: Loss of adipose tissue and plasma phospholipids: Relationship to survival in advanced cancer patients. Clin Nutr. 29:482–487. 2010.PubMed/NCBI View Article : Google Scholar
12	Liu H, Luo J, Guillory B, Chen JA, Zang P, Yoeli JK, Hernandez Y, Lee II, Anderson B, Storie M, et al: Ghrelin ameliorates tumor-induced adipose tissue atrophy and inflammation via Ghrelin receptor-dependent and -independent pathways. Oncotarget. 11:3286–3302. 2020.PubMed/NCBI View Article : Google Scholar
13	Ding Z, Sun D, Han J, Shen L, Yang F, Sah S, Sui X and Wu G: Novel noncoding RNA CircPTK2 regulates lipolysis and adipogenesis in cachexia. Mol Metab. 53(101310)2021.PubMed/NCBI View Article : Google Scholar
14	Mantovani G, Macciò A, Esu S, Lai P, Santona MC, Massa E, Dessì D, Melis GB and Del Giacco GS: Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer. 33:602–607. 1997.PubMed/NCBI View Article : Google Scholar
15	Batista ML Jr, Peres SB, McDonald ME, Alcantara PSM, Olivan M, Otoch JP, Farmer SR and Seelaender M: Adipose tissue inflammation and cancer cachexia: Possible role of nuclear transcription factors. Cytokine. 57:9–16. 2012.PubMed/NCBI View Article : Google Scholar
16	Argilés JM, Stemmler B, López-Soriano FJ and Busquets S: Inter-tissue communication in cancer cachexia. Nat Rev Endocrinol. 15:9–20. 2018.PubMed/NCBI View Article : Google Scholar
17	Bruera E, Ernst S, Hagen N, Spachynski K, Belzile M, Hanson J, Summers N, Brown B, Dulude H and Gallant G: Effectiveness of megestrol acetate in patients with advanced cancer: A randomized, double-blind, crossover study. Cancer Prev Control. 2:74–78. 1998.PubMed/NCBI
18	Greig CA, Johns N, Gray C, MacDonald A, Stephens NA, Skipworth RJ, Fallon M, Wall L, Fox GM and Fearon KC: Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy. Support Care Cancer. 22:1269–1275. 2014.PubMed/NCBI View Article : Google Scholar
19	Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL and Bort-Martí S: Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev: Mar 28, 2013 (Epub ahead of print).
20	Mantovani G, Macciò A, Lai P, Massa E, Ghiani M and Santona MC: Cytokine activity in cancer-related anorexia/cachexia: Role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol. 25 (Suppl 6):S45–S52. 1998.PubMed/NCBI
21	Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, Rowland KM Jr, Camoriano JK, Novotny PJ and Christensen BJ: Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol. 17:3299–3306. 1999.PubMed/NCBI View Article : Google Scholar
22	House L, Seminerio MJ, Mirkov S, Ramirez J, Skor M, Sachleben JR, Isikbay M, Singhal H, Greene GL, Vander Griend D, et al: Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica. 48:973–983. 2018.PubMed/NCBI View Article : Google Scholar
23	Cao C, Zhou JY, Xie SW, Guo XJ, Li GT, Gong YJ, Yang WJ, Li Z, Zhong RH, Shao HH and Zhu Y: Metformin enhances nomegestrol acetate suppressing growth of endometrial cancer cells and may correlate to downregulating mTOR activity in vitro and in vivo. Int J Mol Sci. 20(3308)2019.PubMed/NCBI View Article : Google Scholar
24	Ruan X, Seeger H and Mueck AO: The pharmacology of nomegestrol acetate. Maturitas. 71:345–353. 2012.PubMed/NCBI View Article : Google Scholar
25	Penna F, Busquets S and Argilés JM: Experimental cancer cachexia: Evolving strategies for getting closer to the human scenario. Semin Cell Dev Biol. 54:20–27. 2016.PubMed/NCBI View Article : Google Scholar
26	Conte E, Camerino GM, Mele A, De Bellis M, Pierno S, Rana F, Fonzino A, Caloiero R, Rizzi L, Bresciani E, et al: Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia. J Cachexia Sarcopenia Muscle. 8:386–404. 2017.PubMed/NCBI View Article : Google Scholar
27	Sirago G, Conte E, Fracasso F, Cormio A, Fehrentz JA, Martinez J, Musicco C, Camerino GM, Fonzino A, Rizzi L, et al: Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia. Sci Rep. 7(13017)2017.PubMed/NCBI View Article : Google Scholar
28	Garcia JM, Scherer T, Chen JA, Guillory B, Nassif A, Papusha V, Smiechowska J, Asnicar M, Buettner C and Smith RG: Inhibition of cisplatin-induced lipid catabolism and weight loss by ghrelin in male mice. Endocrinology. 154:3118–3129. 2013.PubMed/NCBI View Article : Google Scholar
29	Vojtek M, Gonçalves-Monteiro S, Pinto E, Kalivodová S, Almeida A, Marques MPM, Batista de Carvalho ALM, Martins CB, Mota-Filipe H, Ferreira IMPLVO and Diniz C: Preclinical pharmacokinetics and biodistribution of anticancer dinuclear palladium(II)-spermine complex (Pd₂Spm) in mice. Pharmaceuticals (Basel). 14(173)2021.PubMed/NCBI View Article : Google Scholar
30	Conte E, Bresciani E, Rizzi L, Cappellari O, De Luca A, Torsello A and Liantonio A: Cisplatin-induced skeletal muscle dysfunction: Mechanisms and counteracting therapeutic strategies. Int J Mol Sci. 21(1242)2020.PubMed/NCBI View Article : Google Scholar
31	Malik NM, Moore GBT, Smith G, Liu YL, Sanger GJ and Andrews PLR: Behavioural and hypothalamic molecular effects of the anti-cancer agent cisplatin in the rat: A model of chemotherapy-related malaise? Pharmacol Biochem Behav. 83:9–20. 2006.PubMed/NCBI View Article : Google Scholar
32	Brierley DI, Harman JR, Giallourou N, Leishman E, Roashan AE, Mellows BAD, Bradshaw HB, Swann JR, Patel K, Whalley BJ and Williams CM: Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol. J Cachexia Sarcopenia Muscle. 10:844–859. 2019.PubMed/NCBI View Article : Google Scholar
33	Malik NM, Liu YL, Cole N, Sanger GJ and Andrews PL: Differential effects of dexamethasone, ondansetron and a tachykinin NK1 receptor antagonist (GR205171) on cisplatin-induced changes in behaviour, food intake, pica and gastric function in rats. Eur J Pharmacol. 555:164–173. 2007.PubMed/NCBI View Article : Google Scholar
34	Bing C and Trayhurn P: New insights into adipose tissue atrophy in cancer cachexia. Proc Nutr Soc. 68:385–392. 2009.PubMed/NCBI View Article : Google Scholar
35	Patel HJ and Patel BM: TNF-α and cancer cachexia: Molecular insights and clinical implications. Life Sci. 170:56–63. 2017.PubMed/NCBI View Article : Google Scholar
36	Sherry BA, Gelin J, Fong Y, Marano M, Wei H, Cerami A, Lowry SF, Lundholm KG and Moldawer LL: Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J. 3:1956–1962. 1989.PubMed/NCBI View Article : Google Scholar
37	Fearon KC, Glass DJ and Guttridge DC: Cancer cachexia: Mediators, signaling, and metabolic pathways. Cell Metab. 16:153–166. 2012.PubMed/NCBI View Article : Google Scholar
38	Han J, Meng QY, Shen L and Wu GH: Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning. Lipids Health Dis. 17(14)2018.PubMed/NCBI View Article : Google Scholar
39	Chi JY, Wu ZH, Choi CHJ, Nguyen L, Tegegne S, Ackerman SE, Crane A, Marchildon F, Tessier-Lavigne M and Cohen P: Three-dimensional adipose tissue imaging reveals regional variation in beige fat biogenesis and PRDM16-dependent sympathetic neurite density. Cell Metab. 27:226–236.e3. 2018.PubMed/NCBI View Article : Google Scholar
40	Johnson J, Canning J, Kaneko T, Pru JK and Tilly JL: Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature. 428:145–150. 2004.PubMed/NCBI View Article : Google Scholar
41	Silvério R, Lira FS, Oyama LM, Oller do Nascimento CM, Otoch JP, Alcântara PSM, Batista ML Jr and Seelaender M: Lipases and lipid droplet-associated protein expression in subcutaneous white adipose tissue of cachectic patients with cancer. Lipids Health Dis. 16(159)2017.PubMed/NCBI View Article : Google Scholar
42	Das SK, Eder S, Schauer S, Diwoky C, Temmel H, Guertl B, Gorkiewicz G, Tamilarasan KP, Kumari P, Trauner M, et al: Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 333:233–238. 2011.PubMed/NCBI View Article : Google Scholar
43	Kliewer KL, Ke JY, Tian M, Cole RM, Andridge RR and Belury MA: Adipose tissue lipolysis and energy metabolism in early cancer cachexia in mice. Cancer Biol Ther. 16:886–897. 2015.PubMed/NCBI View Article : Google Scholar
44	Batista ML Jr, Neves RX, Peres SB, Yamashita AS, Shida CS, Farmer SR and Seelaender M: Heterogeneous time-dependent response of adipose tissue during the development of cancer cachexia. J Endocrinol. 215:363–373. 2012.PubMed/NCBI View Article : Google Scholar
45	Kim JB, Wright HM, Wright M and Spiegelman BM: ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci USA. 95:4333–4337. 1998.PubMed/NCBI View Article : Google Scholar
46	Wang LF, Miao LJ, Wang XN, Huang CC, Qian YS, Huang X, Wang XL, Jin WZ, Ji GJ, Fu M, et al: CD38 deficiency suppresses adipogenesis and lipogenesis in adipose tissues through activating Sirt1/PPARγ signaling pathway. J Cell Mol Med. 22:101–110. 2018.PubMed/NCBI View Article : Google Scholar
47	Busquets S, Serpe R, Sirisi S, Toledo M, Coutinho J, Martínez R, Orpí M, López-Soriano FJ and Argilés JM: Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia. Clin Nutr. 29:733–737. 2010.PubMed/NCBI View Article : Google Scholar
48	Dorai V, Hazard MC, Paris J and Delansorne R: Lipolytic activity of progesterone and synthetic progestins on rat parametrial adipocytes in vitro. J Pharmacol Exp Ther. 258:620–625. 1991.PubMed/NCBI